Cancer Epidemiology Biomarkers & Prevention, Vol 3, Issue 5 423-428, Copyright © 1994 by American Association for Cancer Research

ARTICLES

Uptake and metabolism of carcinogenic levels of tobacco-specific nitrosamines by Sudanese snuff dippers

SE Murphy, SG Carmella, AM Idris and D Hoffmann
American Health Foundation, Valhalla, New York 10595.

It was recently reported that toombak, a type of snuff used in the Sudan, contained unusually high levels of tobacco-specific nitrosamines. To estimate the internal dose of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) received by individuals who use this type of tobacco, urine from a group of users was analyzed for 2 metabolites of NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its O-glucuronide, NNAL-Gluc. NNK is a strong lung carcinogen believed to contribute to human lung cancer. NNAL is also a lung carcinogen. NNAL and NNAL-Gluc were analyzed by gas chromatography with a nitrosamine selective detector. The average levels detected were 0.39 +/- 0.14 (SD) nmol/ml urine (n = 7) and 0.88 +/- 0.50 nmol/ml urine (n = 7), respectively. In a 24-h period, these individuals would excrete from 0.12 to 0.44 mg of these two metabolites (expressed per mg NNAL). Therefore, assuming chronic toombak use, the minimum daily dose of NNK to which these users were exposed was 0.12-0.44 mg. This is the highest documented uptake of a nonoccupational carcinogen. Two diastereomers of NNAL-Gluc were present in all urine samples analyzed. Previously, these two diastereomers were identified in the urine of an NNK-treated patas monkey but only one was detected in the urine of NNK-treated rats. The level of the 4-hydroxy-1-(3-pyridyl)-1-butanone releasing hemoglobin adduct was also quantified in these individuals. This adduct is believed to be a measure of NNK activation. The levels ranged from 68 to 323 fmol/g hemoglobin [mean, 148 +/- 104 (SD)]. The wide range of adduct levels which were observed suggests that despite similar levels of NNK exposure, there are significant differences in the ability of individuals in this population to activate NNK, as well as potential differences in their cancer risk.

This article has been cited by other articles:

				I. Stepanov, P. Upadhyaya, S. G. Carmella, R. Feuer, J. Jensen, D. K. Hatsukami, and S. S. Hecht Extensive Metabolic Activation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Smokers Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1764 - 1773. [Abstract] [Full Text] [PDF]

				G. Chen, R. W. Dellinger, D. Sun, T. E. Spratt, and P. Lazarus Glucuronidation of Tobacco-Specific Nitrosamines by UGT2B10 Drug Metab. Dispos., May 1, 2008; 36(5): 824 - 830. [Abstract] [Full Text] [PDF]

				C. J. Gallagher, J. E. Muscat, A. N. Hicks, Y. Zheng, A.-M. Dyer, G. A. Chase, J. Richie, and P. Lazarus The UDP-Glucuronosyltransferase 2B17 Gene Deletion Polymorphism: Sex-Specific Association with Urinary 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronidation Phenotype and Risk for Lung Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 823 - 828. [Abstract] [Full Text] [PDF]

				D. Wiener, J.-L. Fang, N. Dossett, and P. Lazarus Correlation between UDP-Glucuronosyltransferase Genotypes and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Glucuronidation Phenotype in Human Liver Microsomes Cancer Res., February 1, 2004; 64(3): 1190 - 1196. [Abstract] [Full Text] [PDF]

				S. S. Hecht Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer Carcinogenesis, June 1, 2002; 23(6): 907 - 922. [Abstract] [Full Text] [PDF]

				Q. Ren, S. E. Murphy, Z. Zheng, and P. Lazarus O-Glucuronidation of the Lung Carcinogen 4-(methylnitrosamino)-1- (3-Pyridyl)-1-Butanol (nnal) by Human Udp-Glucuronosyltransferases 2b7 and 1a9 Drug Metab. Dispos., November 1, 2000; 28(11): 1352 - 1360. [Abstract] [Full Text]

				K. Straif, S. K Weiland, M. Bungers, D. Holthenrich, D. Taeger, S. Yi, and U. Keil Exposure to high concentrations of nitrosamines and cancer mortality among a cohort of rubber workers Occup. Environ. Med., March 1, 2000; 57(3): 180 - 187. [Abstract] [Full Text]

				F. Huhtasaari, V. Lundberg, M. Eliasson, U. Janlert, and K. Asplund Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men J. Am. Coll. Cardiol., November 15, 1999; 34(6): 1784 - 1790. [Abstract] [Full Text] [PDF]

				Q. Ren, S. E. Murphy, A. J. Dannenberg, J. Y. Park, T. R. Tephly, and P. Lazarus Glucuronidation of the Lung Carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by Rat UDP-Glucuronosyltransferase 2B1 Drug Metab. Dispos., September 1, 1999; 27(9): 1010 - 1016. [Abstract] [Full Text]

				S. G. Carmella, M. Ye, P. Upadhyaya, and S. S. Hecht Stereochemistry of Metabolites of a Tobacco-specific Lung Carcinogen in Smokers' Urine Cancer Res., August 1, 1999; 59(15): 3602 - 3605. [Abstract] [Full Text] [PDF]

				G. M. Lackmann, U. Salzberger, U. Tollner, M. Chen, S. G. Carmella, and S. S. Hecht Metabolites of a Tobacco-Specific Carcinogen in Urine From Newborns J Natl Cancer Inst, March 3, 1999; 91(5): 459 - 465. [Abstract] [Full Text] [PDF]